### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Burcau



### 

# (43) International Publication Date 30 January 2003 (30.01.2003)

### **PCT**

# (10) International Publication Number WO 03/008608 A2

(51) International Patent Classification7: C12P 13/00

(21) International Application Number: PCT/EP02/07366

(22) International Filing Date: 3 July 2002 (03.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

101 35 053.8 18 July 2001 (18.07.2001) DI 60/306,869 23 July 2001 (23.07.2001) US

(71) Applicant (for all designated States except US): DE-GUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): RIEPING, Mechthild [DE/DE]; Mönkebergstrasse 1, 33619 Bieleseld (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR. KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH. GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declaration under Rule 4.17:


- of inventorship (Rule 4.17(iv)) for US only

#### Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY WHICH CONTAIN AN ENHANCED PHOE GENE



(57) Abstract: The invention relates to a process for the preparation of L-amino acids, in particular L-threonine, in which the following steps are carried out: a) fermentation of microorganisms of the Enterobacteriaceae family which produce the desired L-amino acid and in which at least the phoE gene, or the nucleotide sequence which codes for this, is enhanced, in particular over-expressed, b) concentration of the desired L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the desired L-amino acid.

)3/008608 A2

# Process for the Preparation of L-Amino Acids using Strains of the Enterobacteriaceae Family which Contain an Enhanced phoE Gene

Field of the Invention

5 This invention relates to a process for the fermentative preparation of L-amino acids, in particular L-threonine, using strains of the Enterobacteriaceae family in which at least the phoE gene is enhanced.

Prior Art

manner.

- 10 L-Amino acids, in particular L-threonine, are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.
- It is known to prepare L-amino acids by fermentation of strains of Enterobacteriaceae, in particular Escherichia coli (E. coli) and Serratia marcescens. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as e.g.
- 20 stirring and supply of oxygen, or the composition of the nutrient media, such as e.g. the sugar concentration during the fermentation, or the working up to the product form, by e.g. ion exchange chromatography, or the intrinsic output properties of the microorganism itself.
- 25 Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites, such as e.g. the threonine analogue  $\alpha$ -amino- $\beta$ -hydroxyvaleric acid (AHV), or are auxotrophic for metabolites of regulatory importance and produce L-amino acid, such as e.g. L-threonine, are obtained in this

2

Methods of the recombinant DNA technique have also been employed for some years for improving the strain of strains of the Enterobacteriaceae family which produce Lamino acids, by amplifying individual amino acid 5 biosynthesis genes and investigating the effect on the production.

Object of the Invention

The object of the invention is to provide new measures for improved fermentative preparation of L-amino acids, in 10 particular L-threonine.

Summary of the Invention

The invention provides a process for the fermentative preparation of L-amino acids, in particular L-threonine, using microorganisms of the Enterobacteriaceae family which 15 in particular already produce L-amino acids and in which at least the nucleotide sequence which codes for the phoE gene is enhanced.

Detailed Description of the Invention

Where L-amino acids or amino acids are mentioned in the 20 following, this means one or more amino acids, including their salts, chosen from the group consisting of Lasparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, Lisoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-25 histidine, L-lysine, L-tryptophan and L-arginine. L-Threonine is particularly preferred.

The term "enhancement" in this connection describes the increase in the intracellular activity of one or more enzymes or proteins in a microorganism which are coded by 30 the corresponding DNA, for example by increasing the number of copies of the gene or genes, using a potent promoter or a gene or allele which codes for a corresponding enzyme or

20

protein with a high activity, and optionally combining these measures.

By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on that of the wild-type protein or the activity or concentration of the protein in the starting microorganism.

- 10 The process comprises carrying out the following steps:
  - a) fermentation of microorganisms of the Enterobacteriaceae family in which at least the phoE gene is enhanced,
- b) concentration of the corresponding L-amino acid in the medium or in the cells of the microorganisms of the Enterobacteriaceae family, and
  - c) isolation of the desired L-amino acid, constituents of the fermentation broth and/or the biomass in its entirety or portions (> 0 to 100 %) thereof optionally remaining in the product.

The microorganisms which the present invention provides can produce L-amino acids from glucose, sucrose, lactose, fructose, maltose, molasses, optionally starch, optionally cellulose or from glycerol and ethanol. They are representatives of the Enterobacteriaceae family chosen

- from the genera Escherichia, Erwinia, Providencia and Serratia. The genera Escherichia and Serratia are preferred. Of the genus Escherichia the species Escherichia coli and of the genus Serratia the species Serratia
- 30 marcescens are to be mentioned in particular.

WO 03/008608 PCT/EP02/07366

Suitable strains, which produce L-threonine in particular, of the genus Escherichia, in particular of the species Escherichia coli, are, for example

Escherichia coli TF427

5 Escherichia coli H4578

Escherichia coli KY10935

Escherichia coli VNIIgenetika MG442

Escherichia coli VNIIgenetika M1

Escherichia coli VNIIgenetika 472T23

10 Escherichia coli BKIIM B-3996

Escherichia coli kat 13

Escherichia coli KCCM-10132.

Suitable L-threonine-producing strains of the genus Serratia, in particular of the species Serratia marcescens, 15 are, for example

> Serratia marcescens HNr21 Serratia marcescens TLr156 Serratia marcescens T2000.

Strains from the Enterobacteriaceae family which produce L20 threonine preferably have, inter alia, one or more genetic or phenotypic features chosen from the group consisting of: resistance to α-amino-β-hydroxyvaleric acid, resistance to thialysine, resistance to ethionine, resistance to α-methylserine, resistance to diaminosuccinic acid,
25 resistance to α-aminobutyric acid, resistance to borrelidin, resistance to rifampicin, resistance to valine analogues, such as, for example, valine hydroxamate, resistance to purine analogues, such as, for example, 6-dimethylaminopurine, a need for L-methionine, optionally a partial and compensable need for L-isoleucine, a need for meso-diaminopimelic acid, auxotrophy in respect of threonine-containing dipeptides, resistance to L-threonine, resistance to L-homoserine, resistance to L-lysine,

resistance to L-methionine, resistance to L-glutamic acid,

resistance to L-aspartate, resistance to L-leucine, resistance to L-phenylalanine, resistance to L-serine, resistance to L-cysteine, resistance to L-valine, sensitivity to fluoropyruvate, defective threonine 5 dehydrogenase, optionally an ability for sucrose utilization, enhancement of the threonine operon, enhancement of homoserine dehydrogenase I-aspartate kinase I, preferably of the feed back resistant form, enhancement of homoserine kinase, enhancement of threonine synthase, 10 enhancement of aspartate kinase, optionally of the feed back resistant form, enhancement of aspartate semialdehyde dehydrogenase, enhancement of phosphoenol pyruvate carboxylase, optionally of the feed back resistant form, enhancement of phosphoenol pyruvate synthase, enhancement 15 of transhydrogenase, enhancement of the RhtB gene product, enhancement of the RhtC gene product, enhancement of the Yfik gene product, enhancement of a pyruvate carboxylase, and attenuation of acetic acid formation.

It has been found that microorganisms of the
20 Enterobacteriaceae family produce L-amino acids, in
particular L-threonine, in an improved manner after
enhancement, in particular over-expression, of the phoE
gene.

The nucleotide sequences of the genes of Escherichia coli
25 belong to the prior art and can also be found in the genome
sequence of Escherichia coli published by Blattner et al.
(Science 277: 1453-1462 (1997)).

The following information, inter alia, is known from the prior art on the phoE gene:

30 Description: Pore protein E of the outer cell membrane Reference: Overbeeke et al.; Journal of Molecular

Biology 163(4): 513-532 (1983); Cowan et al.; Nature 358 (6389): 727-733 (1992)

Accession No.: AE000132

Alternative gene name: ompE

The nucleic acid sequences can be found in the databanks of the National Center for Biotechnology Information (NCBI) of the National Library of Medicine (Bethesda, MD, USA), the nucleotide sequence databank of the European Molecular Biologies Laboratories (EMBL, Heidelberg, Germany or Cambridge, UK) or the DNA databank of Japan (DDBJ, Mishima, Japan).

The genes described in the text references mentioned can be used according to the invention. Alleles of the genes which result from the degeneracy of the genetic code or due to "sense mutations" of neutral function can furthermore be used.

To achieve an enhancement, for example, expression of the genes or the catalytic properties of the proteins can be increased. The two measures can optionally be combined.

To achieve an over-expression, the number of copies of the corresponding genes can be increased, or the promoter and regulation region or the ribosome binding site upstream of the structural gene can be mutated. Expression cassettes which are incorporated upstream of the structural gene act in the same way. By inducible promoters, it is additionally possible to increase the expression in the course of fermentative L-threonine production. The expression is likewise improved by measures to prolong the life of the m-RNA. Furthermore, the enzyme activity is also increased by preventing the degradation of the enzyme

30 be integrated and amplified in the chromosome.

Alternatively, an over-expression of the genes in question can furthermore be achieved by changing the composition of the media and the culture procedure.

protein. The genes or gene constructs can either be present in plasmids with a varying number of copies, or can

Instructions in this context can be found by the expert, inter alia, in Chang and Cohen (Journal of Bacteriology 134: 1141-1156 (1978)), in Hartley and Gregori (Gene 13: 347-353 (1981)), in Amann and Brosius (Gene 40: 183-190 (1985)), in de Broer et al. (Proceedings of the National Academy of Sciences of the United States of America 80: 21-25 (1983)), in LaVallie et al. (BIO/TECHNOLOGY 11: 187-193 (1993)), in PCT/US97/13359, in Llosa et al. (Plasmid 26: 222-224 (1991)), in Quandt and Klipp (Gene 80: 161-169 (1989)), in Hamilton et al. (Journal of Bacteriology 171: 4617-4622 (1989)), in Jensen and Hammer (Biotechnology and Bioengineering 58: 191-195 (1998)) and in known textbooks of genetics and molecular biology.

Plasmid vectors which are capable of replication in

Enterobacteriaceae, such as e.g. cloning vectors derived from pACYC184 (Bartolomé et al.; Gene 102: 75-78 (1991)), pTrc99A (Amann et al.; (Gene 69: 301-315 (1988)) or pSC101 derivatives (Vocke and Bastia; Proceedings of the National Academy of Sciences of the United States of America 80

(21): 6557-6561 (1983)) can be used. A strain transformed with a plasmid vector, where the plasmid vector carries at least the phoE gene, or the nucleotide sequence which codes for this, can be employed in a process according to the invention.

25 It is also possible to transfer mutations which affect the expression of the particular gene into various strains by sequence exchange (Hamilton et al.; Journal of Bacteriology 171: 4617-4622 (1989)), conjugation or transduction.

It may furthermore be advantageous for the production of L30 amino acids, in particular L-threonine, with strains of the
Enterobacteriaceae family, in addition to enhancement of
the phoE gene, for one or more enzymes of the known
threonine biosynthesis pathway or enzymes of anaplerotic
metabolism or enzymes for the production of reduced
35 nicotinamide adenine dinucleotide phosphate or enzymes of

glycolysis or PTS enzymes or enzymes of sulfur metabolism to be enhanced.

Thus, for example, at the same time one or more of the genes chosen from the group consisting of

- the thrABC operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase (US-A-4,278,765),
  - the pyc gene of Corynebacterium glutamicum which codes for pyruvate carboxylase (WO 99/18228),
- the pps gene which codes for phosphoenol pyruvate synthase (Molecular and General Genetics 231(2): 332-336 (1992)),
  - the ppc gene which codes for phosphoenol pyruvate carboxylase (Gene 31: 279-283 (1984)),
- the pntA and pntB genes which code for transhydrogenase (European Journal of Biochemistry 158: 647-653 (1986)),
  - the rhtB gene which imparts homoserine resistance (EP-A-0 994 190),
- the mqo gene which codes for malate:quinone oxidoreductase (WO 02/06459),
  - the rhtC gene which imparts threonine resistance (EP-A-1 013 765),
  - the thrE gene of Corynebacterium glutamicum which codes for the threonine export protein (WO 01/92545),
- 25 the gdhA gene which codes for glutamate dehydrogenase (Nucleic Acids Research 11: 5257-5266 (1983); Gene 23: 199-209 (1983)),

- the hns gene which codes for the DNA-binding protein HLP-II (Molecular and General Genetics 212: 199-202 (1988)),
- the pgm gene which codes for phosphoglucomutase (Journal of Bacteriology 176: 5847-5851 (1994)),
  - the fba gene which codes for fructose biphosphate aldolase (Biochemical Journal 257: 529-534 (1989)),
- the ptsH gene of the ptsHIcrr operon which codes for the phosphohistidine protein hexose phosphotransferase of
   the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
  - the ptsI gene of the ptsHIcrr operon which codes for enzyme I of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
- the crr gene of the ptsHIcrr operon which codes for the glucose-specific IIA component of the phosphotransferase system PTS (Journal of Biological Chemistry 262: 16241-16253 (1987)),
- the ptsG gene which codes for the glucose-specific IIBC component (Journal of Biological Chemistry 261: 16398-16403 (1986)),
  - the 1rp gene which codes for the regulator of the leucine regulon (Journal of Biological Chemistry 266: 10768-10774 (1991)),
- of Biological Chemistry 261: 12414-12419 (1986)) and is also known by the name groES,
- the ahpC gene of the ahpCF operon which codes for the small sub-unit of alkyl hydroperoxide reductase
   (Proceedings of the National Academy of Sciences of the United States of America 92: 7617-7621 (1995)),

WO 03/008608 10

- the ahpF gene of the ahpCF operon which codes for the large sub-unit of alkyl hydroperoxide reductase (Proceedings of the National Academy of Sciences of the United States of America 92: 7617-7621 (1995)),
- 5 the cysk gene which codes for cysteine synthase A (Journal of Bacteriology 170: 3150-3157 (1988)),
  - the cysB gene which codes for the regulator of the cys regulon (Journal of Biological Chemistry 262: 5999-6005 (1987)),
- 10 the cysJ gene of the cysJIH operon which codes for the flavoprotein of NADPH sulfite reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989)),
- the cysI gene of the cysJIH operon which codes for the 15 haemoprotein of NADPH sulfite reductase (Journal of Biological Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989)),
- the cysH gene of the cysJIH operon which codes for adenylyl sulfate reductase (Journal of Biological 20 Chemistry 264: 15796-15808 (1989), Journal of Biological Chemistry 264: 15726-15737 (1989)),
  - the phoB gene of the phoBR operon which codes for the positive regulator PhoB of the pho regulon (Journal of Molecular Biology 190 (1): 37-44 (1986)),
- 25 the phoR gene of the phoBR operon which codes for the sensor protein of the pho regulon (Journal of Molecular Biology 192 (3): 549-556 (1986)),
- the malE gene which codes for the periplasmic binding protein of maltose transport (Journal of Biological 30 Chemistry 259 (16): 10606-10613 (1984)),

 the pykF gene which codes for fructose-stimulated pyruvate kinase I (Journal of Bacteriology 177 (19):

5719-5722 (1995)),

- the pfkB gene which codes for 6-phosphofructokinase II 5 (Gene 28 (3): 337-342 (1984)),
  - the talB gene which codes for transaldolase B (Journal of Bacteriology 177 (20): 5930-5936 (1995)),
  - the rseA gene of the rseABC operon which codes for a membrane protein with anti-sigmaE activity (Molecular Microbiology 24 (2): 355-371 (1997)),
  - the rseC gene of the rseABC operon which codes for a global regulator of the sigmaE factor (Molecular Microbiology 24 (2): 355-371 (1997)),
- the sodA gene which codes for superoxide dismutase 15 (Journal of Bacteriology 155 (3): 1078-1087 (1983)),
  - the sucA gene of the sucABCD operon which codes for the decarboxylase sub-unit of 2-ketoglutarate dehydrogenase (European Journal of Biochemistry 141 (2): 351-359 (1984)),
- 20 the sucB gene of the sucABCD operon which codes for the dihydrolipoyltranssuccinase E2 sub-unit of 2ketoglutarate dehydrogenase (European Journal of Biochemistry 141 (2): 361-374 (1984)),
- the sucC gene of the sucABCD operon which codes for the 25  $\beta$ -sub-unit of succinyl-CoA synthetase (Biochemistry 24 (22): 6245-6252 (1985)) and
  - the sucD gene of the sucABCD operon which codes for the  $\alpha$ -sub-unit of succinyl-CoA synthetase (Biochemistry 24 (22): 6245-6252 (1985)),
- 30 can be enhanced, in particular over-expressed.

It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, in addition to enhancement of the phoE gene, for one or more of the genes chosen from the group consisting of

- 5 the tdh gene which codes for threonine dehydrogenase (Journal of Bacteriology 169: 4716-4721 (1987)),
  - the mdh gene which codes for malate dehydrogenase (E.C.
     1.1.37) (Archives in Microbiology 149: 36-42 (1987)),
- the gene product of the open reading frame (orf) yjfA
   (Accession Number AAC77180 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
  - the gene product of the open reading frame (orf) ytfP (Accession Number AAC77179 of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA)),
- the pckA gene which codes for the enzyme phosphoenol pyruvate carboxykinase (Journal of Bacteriology 172: 7151-7156 (1990)),
  - the poxB gene which codes for pyruvate oxidase (Nucleic Acids Research 14(13): 5449-5460 (1986)),
- 20 the aceA gene which codes for the enzyme isocitrate lyase (Journal of Bacteriology 170: 4528-4536 (1988)),

- the dgsA gene which codes for the DgsA regulator of the phosphotransferase system (Bioscience, Biotechnology and Biochemistry 59: 256-251 (1995)) and is also known under the name of the mlc gene,
  - the fruR gene which codes for the fructose repressor (Molecular and General Genetics 226: 332-336 (1991)) and is also known under the name of the cra gene and

the rpoS gene which codes for the sigma<sup>38</sup> factor (WO 01/05939) and is also known under the name of the katF gene,

to be attenuated, in particular eliminated or for the 5 expression thereof to be reduced.

The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or a gene or allele which codes for a corresponding enzyme with a low activity or inactivates the corresponding enzyme (protein) or gene, and optionally combining these measures.

- By attenuation measures, the activity or concentration of 15 the corresponding protein is in general reduced to 0 to 75%, 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein or of the activity or concentration of the protein in the starting microorganism.
- 20 It may furthermore be advantageous for the production of L-amino acids, in particular L-threonine, in addition to enhancement of the phoE gene, to eliminate undesirable side reactions (Nakayama: "Breeding of Amino Acid Producing Microorganisms", in: Overproduction of Microbial Products, 25 Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London,
  - UK, 1982).

The microorganisms produced according to the invention can be cultured in the batch process (batch culture), the fed batch process (feed process) or the repeated fed batch process (repetitive feed process). A summary of known culture methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik [Bioprocess Technology 1. Introduction

to Bioprocess Technology (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen [Bioreactors and Peripheral Equipment] (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

- 5 The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology 10 (Washington D.C., USA, 1981).
  - Sugars and carbohydrates, such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and optionally cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as
- e.g. palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.
- Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. The sources of nitrogen

can be used individually or as a mixture.

- Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus.
- 30 The culture medium must furthermore comprise salts of metals, such as e.g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the abovementioned substances.

Suitable precursors can moreover be added to the culture medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.

- 5 Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture.

  Antifoams, such as e.g. fatty acid polyglycol esters, can
- 10 be employed to control the development of foam. Suitable substances having a selective action, e.g. antibiotics, can be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are
- 15 introduced into the culture. The temperature of the culture is usually 25°C to 45°C, and preferably 30°C to 40°C. Culturing is continued until a maximum of L-amino acids or L-threonine has formed. This target is usually reached within 10 hours to 160 hours.
- 20 The analysis of L-amino acids can be carried out by anion exchange chromatography with subsequent ninhydrin derivation, as described by Spackman et al. (Analytical Chemistry 30: 1190-1206 (1958)), or it can take place by reversed phase HPLC as described by Lindroth et al.
- 25 (Analytical Chemistry 51: 1167-1174 (1979)).
  - The process according to the invention is used for the fermentative preparation of L-amino acids, such as, for example, L-threonine, L-isoleucine, L-valine, L-methionine, L-homoserine and L-lysine, in particular L-threonine.
- 30 The present invention is explained in more detail in the following with the aid of embodiment examples.
  - The minimal (M9) and complete media (LB) for Escherichia coli used are described by J.H. Miller (A Short Course in

Bacterial Genetics (1992), Cold Spring Harbor Laboratory
Press). The isolation of plasmid DNA from Escherichia coli
and all techniques of restriction, ligation, Klenow and
alkaline phosphatase treatment are carried out by the

5 method of Sambrook et al. (Molecular Cloning - A Laboratory
Manual (1989) Cold Spring Harbor Laboratory Press). Unless
described otherwise, the transformation of Escherichia coli
is carried out by the method of Chung et al. (Proceedings
of the National Academy of Sciences of the United States of
10 America 86: 2172-2175 (1989)).

The incubation temperature for the preparation of strains and transformants is 37°C.

### Example 1

Construction of the expression plasmid pTrc99AphoE

- The phoE gene from E. coli K12 is amplified using the polymerase chain reaction (PCR) and synthetic oligonucleotides. Starting from the nucleotide sequence of the phoE gene in E. coli K12 MG1655 (Accession Number AE000132, Blattner et al. (Science 277: 1453-1462 (1997)),
- 20 PCR primers are synthesized (MWG Biotech, Ebersberg, Germany). The sequences of the primers are modified such that recognition sites for restriction enzymes are formed. The recognition sequence for XbaI is chosen for the phoE1 primer and the recognition sequence for HindIII for the
- 25 phoE2 primer, which are marked by underlining in the nucleotide sequence shown below:
  - phoE1: 5' CCGCTGAATATTCTAGAGTTAATTAAAATCAGG 3' (SEQ ID
    No. 1)
  - phoE2: 5' CCGGAAGCTTCACATCCGGCAATATTC 3' (SEQ ID No. 2)
- 30 The chromosomal E. coli K12 MG1655 DNA employed for the PCR is isolated according to the manufacturer's instructions with "Giagua Genovicenies 100 O" (GIAGRA, Wilsen, Germany).

A DNA fragment approx. 1100 bp in size can be amplified with the specific primers under standard PCR conditions (Innis et al. (1990) PCR Protocols. A Guide to Methods and Applications, Academic Press) with Pfu-DNA polymerase

- 5 (Promega Corporation, Madison, USA). The PCR product is ligated according to the manufacturer's instructions with the vector pCR-Blunt II-TOPO (Zero Blunt TOPO PCR Cloning Kit, Invitrogen, Groningen, The Netherlands) and transformed into the E. coli strain TOP10. Selection of
- 10 plasmid-carrying cells takes place on LB agar, to which 50  $\mu$ g/ml kanamycin are added. After isolation of the plasmid DNA, the vector pCR-Blunt II-TOPO-phoE is cleaved with the restriction enzymes HindIII and XbaI and, after separation in 0.8% agarose gel, the phoE fragment is
- 15 isolated with the aid of the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany).

The vector pTrc99A (Pharmacia Biotech, Uppsala, Sweden) is cleaved with the enzymes HindIII and XbaI and ligation is carried out with the phoE fragment isolated. The E. coli

- 20 strain XL1-Blue MRF' (Stratagene, La Jolla, USA) is transformed with the ligation batch and plasmid-carrying cells are selected on LB agar, to which 50 μg/ml ampicillin are added. Successful cloning can be demonstrated after plasmid DNA isolation by control cleavage with the enzymes
- 25 SspI and MluI. The plasmid is called pTrc99AphoE (Figure 1).

#### Example 2

Preparation of L-threonine with the strain MG442/pTrc99AphoE

30 The L-threonine-producing E. coli strain MG442 is described in the patent specification US-A- 4,278,765 and deposited as CMIM B-1628 at the Russian National Collection for Industrial Microorganisms (VKPM, Moscow, Russia).

The strain MG442 is transformed with the expression plasmid pTrc99AphoE described in example 1 and with the vector pTrc99A and plasmid-carrying cells are selected on LB agar with 50 µg/ml ampicillin. The strains MG442/pTrc99AphoE and 5 MG442/pTrc99A are formed in this manner. Selected individual colonies are then multiplied further on minimal medium with the following composition: 3.5 g/l Na<sub>2</sub>HPO<sub>4</sub>\*2H<sub>2</sub>O, 1.5 g/l  $KH_2PO_4$ , 1 g/l  $NH_4Cl$ , 0.1 g/l  $MgSO_4*7H_2O$ , 2 g/l glucose, 20 g/l agar, 50 mg/l ampicillin. The formation of 10 L-threonine is checked in batch cultures of 10 ml contained in 100 ml conical flasks. For this, 10 ml of preculture medium of the following composition: 2 g/l yeast extract, 10 g/l  $(NH_4)_2SO_4$ , 1 g/l  $KH_2PO_4$ , 0.5 g/l  $MgSO_4*7H_2O$ , 15 g/l CaCO<sub>3</sub>, 20 g/1 glucose, 50 mg/l ampicillin are inoculated 15 and the batch is incubated for 16 hours at 37°C and 180 rpm on an ESR incubator from Kühner AG (Birsfelden,

250 ul portions of this preculture are transinoculated into 10 ml of production medium (25 g/l (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 2 g/l KH<sub>2</sub>PO<sub>4</sub>,

20 1 g/l MgSO<sub>4</sub>\*7H<sub>2</sub>O, 0.03 g/l FeSO<sub>4</sub>\*7H<sub>2</sub>O, 0.018 g/l MnSO<sub>4</sub>\*1H<sub>2</sub>O, 30 g/l CaCO<sub>3</sub>, 20 g/l glucose, 50 mg/l ampicillin) and the batch is incubated for 48 hours at 37°C. The formation of L-threonine by the starting strain MG442 is investigated in the same manner, but no addition of ampicillin to the

Switzerland).

25 medium takes place. After the incubation the optical density (OD) of the culture suspension is determined with an LP2W photometer from Dr. Lange (Düsseldorf, Germany) at a measurement wavelength of 660 nm.

The concentration of L-threonine formed is then determined 30 in the sterile-filtered culture supernatant with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column reaction with ninhydrin detection.

The result of the experiment is shown in Table 1.

Table 1

Strain	OD (660 nm)	L-Threonine g/l
MG442	5.6	1.4
MG442/pTrc99A	3.8	1.3
MG442/pTrc99AphoE	3.3	2.4

Brief Description of the Figure:

Figure 1: Map of the plasmid pTrc99AphoE containing the phoE gene.

The length data are to be understood as approx. data. The abbreviations and designations used have the following meaning:

• Amp: Ampicillin resistance gene

10 • lacI: Gene for the repressor protein of the tro

• Ptrc: trc promoter region, IPTG-inducible

• phoE: Coding region of the phoE gene

• 5S: 5S rRNA region

15 • rrnBT: rRNA terminator region

The abbreviations for the restriction enzymes have the following meaning

• HindIII: Restriction endonuclease from Haemophilus influenzae

- MluI: Restriction endonuclease from Micrococcus luteus IFO 12992
- SspI: Restriction endonuclease from Sphaerotilus species ATCC 13925
- 5 XbaI: Restriction endonuclease from Xanthomonas campestris

#### What is claimed is:

15

- 1. A process for the preparation of L-amino acids, in particular L-threonine, which comprises carrying out the following steps:
- 5 a) fermentation of microorganisms of the
  Enterobacteriaceae family which produce the desired
  L-amino acid and in which at least the phoE gene,
  or the nucleotide sequence which codes for this, is
  enhanced, in particular over-expressed,
- 10 b) concentration of the desired L-amino acid in the medium or in the cells of the microorganisms, and
  - c) isolation of the desired L-amino acid, constituents of the fermentation broth and/or the biomass in its entirety or portions (> 0 to 100 %) thereof optionally remaining in the product.
  - A process as claimed in claim 1, wherein microorganisms in which further genes of the biosynthesis pathway of the desired L-amino acid are additionally enhanced are employed.
- 20 3. A process as claimed in claim 1, wherein microorganisms in which the metabolic pathways which reduce the formation of the desired L-amino acid are at least partly eliminated are employed.
- A process as claimed in claim 1, wherein the expression
   of the polynucleotide which codes for the phoE gene is increased.
  - 5. A process as claimed in claim 1, wherein the regulatory and/or catalytic properties of the polypeptide (protein) for which the polynucleotide phoE codes are improved or increased.

- 6. A process as claimed in claim 1, wherein, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in which in addition at the same time one or more of the genes chosen from the group consisting of:
  - 6.1 the thrABC operon which codes for aspartate kinase, homoserine dehydrogenase, homoserine kinase and threonine synthase,
- 6.2 the pyc gene which codes for pyruvate carboxylase,
  - 6.3 the pps gene which codes for phosphoenol pyruvate synthase,
  - 6.4 the ppc gene which codes for phosphoenol pyruvate carboxylase,
- 15 6.5 the pntA and pntB genes which code for transhydrogenase,
  - 6.6 the rhtB gene which imparts homoserine resistance,
- 6.7 the mgo gene which codes for malate:quinone oxidoreductase,
  - 6.8 the rhtC gene which imparts threonine resistance,
  - 6.9 the thrE gene which codes for the threonine export protein,
- 25 6.10 the gdhA gene which codes for glutamate dehydrogenase,
  - 6.11 the hns gene which codes for the DNA-binding protein HLP-II,

WO 03/008608 PCT/EP02/07366

	6.12	the pgm gene which codes for phosphoglucomutase,
	6.13	the fba gene which codes for fructose biphosphate aldolase,
5	6.14	the ptsH gene which codes for the phosphohistidine protein hexose phosphotransferase,
	6.15	the ptsI gene which codes for enzyme I of the phosphotransferase system,
10	6.16	the crr gene which codes for the glucose- specific IIA component,
	6.17	the ptsG gene which codes for the glucose- specific IIBC component,
15	6.18	the lrp gene which codes for the regulator of the leucine regulon,
	6.19	the mopB gene which codes for 10 Kd chaperone,
	6.20	the ahpC gene which codes for the small sub- unit of alkyl hydroperoxide reductase,
20	6.21	the ahpF gene which codes for the large sub- unit of alkyl hydroperoxide reductase,
	6.22	the cysK gene which codes for cysteine synthase A,
	6.23	the cysB gene which codes for the regulator of the cys regulon,
25	6.24	the cysJ gene which codes for the flavoprotein of NADPH sulfite reductase,
	6.25	the cysI gene which codes for the haemoprotein of NADPH sulfite reductase,

	0.20	reductase,
	6.27	the phoB gene which codes for the positive regulator PhoB of the pho regulon,
5	6.28	the phoR gene which codes for the sensor protein of the pho regulon,
	6.29	the malE gene which codes for the periplasmic binding protein of maltose transport,
10	6.30	the pykF gene which codes for fructose- stimulated pyruvate kinase I,
	6.31	the pfkB gene which codes for 6-phosphofructokinase II,
	6.32	the talB gene which codes for transaldolase B,
15	6.33	the rseA gene which codes for a membrane protein which acts as a negative regulator on sigmaE activity,
	6.34	the rseC gene which codes for a global regulator of the sigmaE factor,
20	6.35	the sodA gene which codes for superoxide dismutase,
	6.36	the sucA gene which codes for the decarboxylase sub-unit of 2-ketoglutarate dehydrogenase,
25	6.37	the sucB gene which codes for the dihydrolipoyltranssuccinase E2 sub-unit of 2-ketoglutarate dehydrogenase,
	6.38	the sucC gene which codes for the $\beta$ -sub-unit of succinyl-CoA synthetase,


6.39 the sucD gene which codes for the  $\alpha$ -sub-unit of succinyl-CoA synthetase,

is or are enhanced, in particular over-expressed, are fermented.

- 5 7. A process as claimed in claim 1, wherein, for the preparation of L-amino acids, microorganisms of the Enterobacteriaceae family in which in addition at the same time one or more of the genes chosen from the group consisting of:
- 10 7.1 the tdh gene which codes for threonine dehydrogenase,
  - 7.2 the mdh gene which codes for malate dehydrogenase,
- 7.3 the gene product of the open reading frame (orf) yjfA,
  - 7.4 the gene product of the open reading frame (orf) ytfP,
  - 7.5 the pckA gene which codes for phosphoenol pyruvate carboxykinase,
- 20 7.6 the poxB gene which codes for pyruvate oxidase,
  - 7.7 the aceA gene which codes for isocitrate lyase,
  - 7.8 the dgsA gene which codes for the DgsA regulator of the phosphotransferase system,
- 7.9 the fruR gene which codes for the fructose repressor,
  - 7.10 the rpoS gene which codes for the sigma<sup>38</sup> factor

is or are attenuated, in particular eliminated or reduced in expression, are fermented.

Figure 1:



#### SEQUENCE PROTOCOL

```
<110> Degussa AG
 5
      <120> Process for the preparation of L-amino acids using
              strains of the Enterobacteriaceae family which contain an
              enhanced phoE gene
10
     <130> 020279BT
    · <160> 2
      <170> PatentIn version 3.1
15
      <210> 1
      <211> 33
<212> DNA
<213> artificial sequence
20
      <220>
      <221> Primer
      <222> (1)..(33)
<223> phoE1
25
      <400> 1
      ccgctgaata ttctagagtt aattaaaatc agg
                                                                                     33
      <210> 2
<211> 27
<212> DNA
<213> artificial sequence
30
      <220>
      <221> Primer
<222> (1)..(27)
<223> phoE2
35
      <400> 2
40
      ccggaagett cacatccggc aatattc
```

# (19) World Intellectual Property Organization International Bureau



### . 1880 BIN 1881 BIN 1881 BIN 1888 BIN 1

# (43) International Publication Date 30 January 2003 (30.01.2003)

### PCT

# (10) International Publication Number WO 03/008608 A3

(51) International Patent Classification<sup>7</sup>: C12N 15/31, C12P 13/08, 13/04, C07K 14/245, C12P 13/08, C12R 1/19

(21) International Application Number: PCT/EP02/07366

(22) International Filing Date: 3 July 2002 (03.07.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

101 35 053.8 60/306,869

18 July 2001 (18.07.2001) DE 23 July 2001 (23.07.2001) US

(71) Applicant (for all designated States except US): DE-GUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düsseldorf (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): RIEPING, Mechthild [DE/DE]; Mönkebergstrasse 1, 33619 Bielefeld (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK. MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declaration under Rule 4.17:

of inventorship (Rule 4.17(iv)) for US only


#### Published:

with international search report

(88) Date of publication of the international search report: 30 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF L-AMINO ACIDS USING STRAINS OF THE ENTEROBACTERIACEAE FAMILY WHICH CONTAIN AN ENHANCED PHOE GENE



(57) Abstract: The invention relates to a process for the preparation of the control acids, in particular L-threonine, in which is lowing steps are carried out: a) fermentation of microorganisms of the control acid and in which at least the phoE gene, or the nucleotide sequence which codes for this, is enhanced, in particular over-expressed, b) concentration of the desired L-amino acid in the medium or in the cells of the bacteria, and c) isolation of the desired L-amino acid.



PCT/ET 02/07366

A. CLASSIF IPC 7	CATION OF SUBJECT MATTER C12N15/31 C12P13/08 C12P13/0 C12R1:19)	4 C07K14/245 //	(C12P13/08,
According to	International Patent Classification (IPC) or to both national classification	tion and IPC	
B. FIELDS			
	currentation searched (classification system tollowed by classification C12P C12N C07K	n symbols)	
	on searched other than minimum documentation to the extent that so		
Electronic da	ata base consulted during the international search (name of data bas	e and, where practical, search terms t	used)
EPO-In	ternal, WPI Data, PAJ, BIOSIS, MEDLI	NE, EMBASE	
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No.
А	RAO N N ET AL: "Molecular aspect phosphate transport in Escherich1 MOLECULAR MICROBIOLOGY, vol. 4, no. 7, July 1990 (1990-07	a colt."	1-7
	1083-1090, XP008017996 ISSN: 0950-382X abstract		
	EP 0 994 190 A (AJINOMOTO KK) 19 April 2000 (2000-04-19) the whole document example 4 claims 6,7,10,11		1-7
	, <del></del>	-/	
}		•	
ł			•
ļ			
X Furt	ner documents are listed in the continuation of box C.	X Patent family members are I	isted in annex.
* Special ca	regories of cited documents:	later document published after the	international filing date
	ent defining the general state of the art which is not leted to be of particular relevance	or priority date and not in conflict clied to understand the principle invention	or theory underlying the
'E' earlier (	document but published on or after the international tate	"X" document of particular relevance; cannot be considered novel or ca	annot be considered to
which	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of enother	involve an inventive step when the "Y" document of particular relevance;	ne document is taken alone the claimed invention
.O. docriu	n or other special reason (as specified) ent referring to an oral disclosure, use, exhibilion or	cannot be considered to involve document is combined with one	an inventive step when the or more other such docu-
*P* docum	means ent published prior to the international filing date but	ments, such combination being of in the art.	
	nan the priority date claimed actual completion of the international search	*&' document member of the same participation Date of mailing of the internation	
	- 1 June 2003	30/06/2003	
Name and	mailing address of the ISA	Authorized officer	
	European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tet (+31-70) 340-2040, Tx. 31 551 250 ni, Fax: (+31-70) 340-3016	van de Kamp, M	

PCT/EP 02/07366

WO 99 5 R (US); 21 Octo	nent, with Indication, where appropriate, of the relevant passages 3035 A (ALTMAN ELLIOT ; GOKARN RAVI EITEMAN MARK A (US); UNIV GEORG)	Relevant to claim No.
R (US); 21 Octo	3035 A (ALTMAN ELLIOT ;GOKARN RAVI EITEMAN MARK A (US); UNIV GEORG)	1-7
exampl	bber 1999 (1999-10-21)   line 20-24   es 4,7,9,10   31,38,41,49   es 1,4	
of bioc 1999 , AKADEMI HEIDELB ISBN: 0 figure	G: "Biochemical pathways: an atlas themistry and molecular biology" JOHN WILEY & SONS INC. AND SPEKTRUM SCHER VERLAG, NEW YORK — BERG XP002242199 0-471-33130-9 12.3.8-2 12.5.4.2-1, 4.5-1 and 4.5-2	1-7
approac acids" JOURNAL vol. 45 XPOO217 ISSN: 0	R: "Genetic and physiological thes for the production of amino of BIOTECHNOLOGY, 5, no. 1, 1996, pages 1-21, 28648 older 1656 ole document	1-7
the phy acid-pr CRC CRI vol. 15 XP00061 ISSN: 0 figure page 90	1738-8551	1-7
14 July cited i	78 765 A (DEBABOV VLADIMIR G ET AL) y 1981 (1981-07-14) in the application ble document	1-7
15 Marc	43 135 A (AJINOMOTO KK) ch 1995 (1995-03-15) ole document	1-7
23 Sept	37 819 A (KYOWA HAKKO KOGYO KK) tember 1987 (1987-09-23) ole document -/	1-7

Internation I Application No
PCT/EP 02/07366

Category* Citation of document, with indication, where appropriate, of the relevant passages  A DATABASE WPI Section Ch, Week 199148 Derwent Publications Ltd., London, GB; Class B05, AN 1991-351136 XP002241222 & JP 03 236786 A (KYOWA HAKKO KOGYO KK), 22 October 1991 (1991-10-22)	Relevant to claim No.
Section Ch, Week 199148 Derwent Publications Ltd., London, GB; Class B05, AN 1991-351136 XP002241222 & JP 03 236786 A (KYOWA HAKKO KOGYO KK),	1-7
abstract	
WO 03 008605 A (RIEPING MECHTHILD ; DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
WO 03 008606 A (RIEPING MECHTHILD ; DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E WO 03 008607-A (RIEPING MECHTHILD ; DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E WO 03 008609 A (RIEPING MECHTHILD ; DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
WO 03 008610 A (RIEPING MECHTHILD ; DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E WO 03 008611 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E WO 03 008612 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E WO 03 008613 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
E WO 03 008614 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
-/	

Internation I Application No PCT/EP 02/07366

		PC1/EP 02/0/366
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Delevent to stein \$10
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 03 008615 A (RIEPING MECHTHILD ;DEGUSSA (DE)) 30 January 2003 (2003-01-30) the whole document claims 1,6	1-7
Т	WO 03 008600 A (DEGUSSA ;HERMANN THOMAS (DE)) 30 January 2003 (2003-01-30) the whole document claim 1	1-7
		-

PCT/EP 02/07366

				PUIZEP	02/07366
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0994190	A	19-04-2000	RU AU BR CN EP JP KR SK US US US ZA	2144564 C1 4755099 A 9904955 A 1254014 A 0994190 A2 2000116390 A 2000029006 A 140899 A3 6303348 B1 2002102670 A1 2002058314 A1 9906042 A	20-01-2000 20-04-2000 12-12-2000 24-05-2000 19-04-2000 25-04-2000 25-05-2000 16-05-2000 16-10-2001 01-08-2002 16-05-2002 04-04-2000
WO 9953035	Ā	21-10-1999	AU BR CA EP JP WO US	760575 B2 3555999 A 9909615 A 2325598 A1 1073722 A1 2002511250 T 9953035 A1 2003087381 A1 6455284 B1	15-05-2003 01-11-1999 12-12-2000 21-10-1999 07-02-2001 16-04-2002 21-10-1999 08-05-2003 24-09-2002
US 4278765	A	14-07-1981	SU HU	875663 A1 190999 B	15-09-1982 28-12-1986
EP 0643135	A	15-03-1995	AT CZ DE DE DK EP JP SK US EP ES WO RU	203769 T 9401658 A3 69330518 D1 69330518 T2 643135 T3 0643135 A1 3331472 B2 81994 A3 5661012 A 1020526 A2 2158867 T3 9411517 A1 2113484 C1	15-08-2001 15-12-1994 06-09-2001 08-05-2002 15-10-2001 15-03-1995 07-10-2002 10-05-1995 26-08-1997 19-07-2000 16-09-2001 26-05-1994 20-06-1998
EP 0237819	A	23-09-1987	DE DE EP JP JP KR US	3788583 D1 3788583 T2 0237819 A2 2574786 B2 63273487 A 9108634 B1 5017483 A	10-02-1994 19-05-1994 23-09-1987 22-01-1997 10-11-1988 19-10-1991 21-05-1991
JP 3236786	А	22-10-1991	JP	2877414 B2	31-03-1999
WO 03008605	A	30-01-2003	DE WO WO WO	10135053 A1 03008605 A2 03008606 A2 03008607 A2 03008608 A2 03008609 A2 03008610 A2	06-02-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 30-01-2003 20-01-2003

In ation on patent family members

Internation I Application No PCT/EP 02/07366

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03008605	А		WO	03008612 A2	30-01-2003
			WO WO	03008613 A2 03008614 A2	30-01-2003 30-01-2003
			MO	03008615 A2	30-01-2003
W0 03008606	Α	30-01-2003	DE	10135053 A1	06-02-2003
WO 0300000	n	30 01 2000	WO	03008605 A2	30-01-2003
			WO	03008606 A2	30-01-2003
			WO	03008607 A2	30-01-2003
			MO	03008608 A2	30-01-2003
			WO WO	03008609 A2 03008610 A2	30-01-2003 30-01-2003
			MO	03008611 A2	30-01-2003
			WO	03008612 A2	30-01-2003
			WO	03008613 A2	30-01-2003
			WO	03008614 A2	30-01-2003
		الله الله الله الله الله الله الله الله	WO	03008615 A2	30-01-2003
WO 03008607	A	30-01-2003	DE	10135053 A1	06-02-2003
	•		WO WO	03008605 A2 03008606 A2	30-01-2003 30-01-2003
			WO	03008607 A2	30-01-2003
			WO	03008608 A2	30-01-2003
			WO	03008609 A2	30-01-2003
			WO	03008610 A2	30-01-2003
			MO	03008611 A2	30-01-2003 30-01-2003
			WO WO	03008612 A2 03008613 A2	30-01-2003
			WO	03008614 A2	30-01-2003
			WO	03008615 A2	30-01-2003
WO 03008609	Α	30-01-2003	DE	10135053 A1	06-02-2003
,			WO	03008605 A2	30-01-2003
			WO ·	03008606 A2 03008607 A2	30-01-2003 30-01-2003
			WO	03008607 AZ	30-01-2003
			WO	03008609 A2	30-01-2003
			MO	03008610 A2	30-01-2003
			WO	03008611 A2	30 <del>-</del> 01-2003
			MO MO	03008612 A2 03008613 A2	30-01-2003 30-01-2003
٠			WO	03008614 A2	30-01-2003
			WO	03008615 A2	30-01-2003
WO 03008610	A	30-01-2003	DE	10135053 A1	06-02-2003
	••		WO	03008605 A2	30-01-2003
			WO	03008606 A2	30-01-2003
			MO	03008607 A2	30-01-2003
			MO MO	03008608 A2 03008609 A2	30-01-2003 30-01-2003
		•	WO	03008610 A2	30-01-2003
			MO	03008611 A2	30-01-2003
			WO	03008612 A2	30-01-2003
			WO	03008613 A2	30-01-2003
			WO WO	03008614 A2 03008615 A2	30-01-2003 30-01-2003
WO 03008611		20 01 0000			
UA A2000£11	Α	30-01-2003	DE	10135053 A1	06-02-2003

mation on patent family members

Internation 1 Application No PCT/EP 02/07366

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03008611			WO	03008605 A2	30-01-2003
NO 00000011	••		WO	03008606 A2	30-01-2003
			WO	03008607 A2	30-01-2003
			WO	03008608 A2	30-01-2003
			WO	03008609 A2	30-01-2003
			WO	03008610 A2	30-01-2003
			WO	03008611 A2	30-01-2003
			WO	03008612 A2	30-01-2003
			WO	03008613 A2	30-01-2003
			WO	03008614 A2	30-01-2003
			WO	03008615 A2	30-01-2003
WO 03008612	 А	30-01-2003	DE	10135053 A1	06-02-2003
HO 03000012	-	00 01 2000	WO	03008605 A2	30-01-2003
			WO	03008606 A2	30-01-2003
			WO	03008607 A2	30-01-2003
			WO	03008607 A2	30-01-2003
			WO	03008609 A2	30-01-2003
			WO	03008610 A2	30-01-2003
			WO	03008610 A2	30-01-2003
			WO	03008611 A2	30-01-2003
			WO	03008612 A2	30-01-2003
			WO	03008614 A2	30-01-2003
		-	WO	03008614 AZ	30-01-2003
WO 03008613	Α	30-01-2003	DE	10135053 A1	06-02-2003
			WO	03008605 A2	30-01-2003
			WO	03008606 A2	30-01-2003
			WO	03008607 A2	30-01-2003
			WO	03008608 A2	30-01-2003
			WO	03008609 A2	30-01-2003
			MO	03008610 A2	30-01-2003
,			WO	03008611 A2	30-01-2003
			WO	03008612 A2	30-01-2003
			WO	03008613 A2	30-01-2003
			WO	03008614 A2	30-01-2003
			WO	03008615 A2	30-01-2003
WO 03008614	Α	30-01-2003	DE	10135053 A1	06-02-2003
			WO	03008605 A2	30-01-2003
			WO	03008606 A2	30-01-2003
		•	WO	03008607 A2	30-01-2003
			WO	03008608 A2	30-01-2003
			WO	03008609 A2	30-01-2003
			WO	03008610 A2	30-01-2003
			MO	03008611 A2	30-01-2003
			WO	03008612 A2	30-01-2003
			WO	03008613 A2	30-01-2003
			WO	03008614 A2	30-01-2003
			WO	03008615 A2	30-01-2003
WO 03008615	Α	30-01-2003	DE	10135053 A1	06-02-2003
		0. 0. 2000	WO	03008605 A2	30-01-2003
			WO	03008606 A2	30-01-2003
			MO	03008607 A2	30-01-2003
			WO	03008608 A2	30-01-2003
			WO	03008609 A2	30-01-2003
			WO	03008610 A2	30-01-2003

mation on patent family members

PCT/EF 02/07366

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03008615	A		WO	03008611 A2	30-01-2003
			WO	03008612 A2	30-01-2003
			WO	03008613 A2	30-01-2003
			WO	03008614 A2	30-01-2003
			WO	03008615 A2	30-01-2003
WO 03008600	Α	30-01-2003	DE	10135051 A1	06-02-2003
			WO	03008600 A2	30-01-2003
			WO	03008602 A2	30-01-2003
			WO	03008603 A2	30-01-2003
			WO	03008604 A2	30-01-2003
			WO	03008616 A2	30-01-2003